May. 6 at 10:08 PM
$NVO
Monopoly Power: Success in Phase IIIa for oral semaglutide (ages 10-17) secures a monopoly on 20.9M adolescents with zero competition. Approval expected in H2.
Regulatory Moat: The FDA’s move to ban compounded GLP-1s (503B list) will force a massive volume of patients back to official
$NVO products, expanding margins instantly.
Pipeline & M&A: Beyond weight loss, Coramitug (ATTR-CM) has FDA Fast Track. Plus, massive cash flow makes
$NVO the prime candidate to acquire players like
$VKTX to dominate the oral market.
Global Scaling: The GLP-1 market is hitting
$200B+ by 2035. Rapid adoption in China/Brazil and new indications (CVD, Alzheimer’s) fuel a massive long-term narrative.
